nach oben

Current Treatment Options in Oncology

Erschienen in:

01.03.2020 | Skin Cancer (T Ito, Section Editor)

Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

verfasst von: Nasr Alrabadi, MD, Msc, PhD, Razan Haddad, BPharm, Msc, PhDc, Ahmed K. Alomari, MD

Erschienen in: Current Treatment Options in Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Opinion statement

Liquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.PubMed

Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, et al. Plasma circulating tumor DNA levels for the monitoring of melanoma patients: landscape of available technologies and clinical applications. Biomed Res Int. 2017;2017:5986129.PubMedPubMedCentral

Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62–9.PubMed

Lim SY, Lee JH, Diefenbach RJ, Kefford RF, Rizos H. Liquid biomarkers in melanoma: detection and discovery. Mol Cancer. 2018;17(1):8.PubMedPubMedCentral

Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS. Liquid biopsy to monitor melanoma patients. J Dtsch Dermatol Ges. 2018;16(4):405–14.PubMed

Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, et al. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol. 2018;29(2):311–23.PubMed

Diefenbach RJ, Lee JH, Rizos H. Monitoring melanoma using circulating free DNA. Am J Clin Dermatol. 2019;20(1):1–12.PubMed

• Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer. 2018;88:1–9 A prospective cohort study showed that total cfDNA is a sufficient indicator of tumor burden (TB) and can represent a prognostic biomarker for patients with metastatic melanoma.

Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res. 2018;8(10):1947–56.PubMedPubMedCentral

10.

Alrabadi N, Gibson N, Curless K, Cheng L, Kuhar M, Chen S, et al. Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod Pathol. (3):330–7.

11.

Hogan SA, Levesque MP, Cheng PF. Melanoma immunotherapy: next-generation biomarkers. Front Oncol. 2018;8:178.PubMedPubMedCentral

12.

Girotti MR, Gremel G, Lee R, Galvani E, Rothwell D, Viros A, et al. Application of sequencing, liquid biopsies, and patient-derived Xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286–99.PubMed

13.

Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017;36(1):179–90.PubMedPubMedCentral

14.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, et al. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res. 2017;23(19):5729–36.PubMedPubMedCentral

15.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, et al. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. PLoS One. 2017;12(11):e0188174.PubMedPubMedCentral

16.

Forschner A, Battke F, Hadaschik D, Schulze M, Weissgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma: results of a prospective biomarker study. J Immunotherapy of Cancer. 2019;7(1):180.

17.

Hellwig S, Nix DA, Gligorich KM, O'Shea JM, Thomas A, Fuertes CL, et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018;13(7):e0197333.PubMedPubMedCentral

18.

Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2019;13(2):171–84.PubMed

19.

Zhu ML, Zhou L, Sadri N. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma. Virchows Arch. 2018;473(3):371–7.PubMed

20.

Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol. 2018;15(10):639–50.PubMed

21.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–18.PubMedPubMedCentral

22.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130–6.PubMed

23.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 2018;4(5):717–21.PubMedPubMedCentral

24.

Syeda MM, Wiggins JM, Corless B, Spittle C, Karlin-Neumann G, Polsky D. Validation of circulating tumor DNA assays for detection of metastatic melanoma. Methods Mol Biol. 2020;2055:155–80.PubMed

25.

Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999–1002.PubMed

26.

Scaini MC, Pigozzo J, Pizzi M, Manicone M, Chiarion-Sileni V, Zambenedetti P, et al. Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Res. 2019;29(1):89–94.PubMed

27.

Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. Cancer Biomark. 2019;26:271.PubMed

28.

Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M. Melanoma circulating tumor cells: benefits and challenges required for clinical application. Cancer Lett. 2018;424:1–8.PubMed

29.

Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A. 2018;115(10):2467–72.PubMedPubMedCentral

30.

Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, et al. Immunomagnetic-enriched subpopulations of melanoma circulating tumour cells (CTCs) exhibit distinct transcriptome profiles. Cancers. 2019;11(2):157.PubMedCentral

31.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30(5):804–14.PubMedPubMedCentral

32.

Burjanivova T, Malicherova B, Grendar M, Minarikova E, Dusenka R, Vanova B, et al. Detection of BRAFV600E mutation in melanoma patients by digital PCR of circulating DNA. Genet Test Mol Biomarkers. 2019;23(4):241–5.PubMed

33.

Long-Mira E, Ilie M, Chamorey E, Leduff-Blanc F, Montaudie H, Tanga V, et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients. Oncotarget. 2018;9(90):36238–49.PubMedPubMedCentral

34.

Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, et al. Early circulating tumour DNA variations predict tumour response in melanoma patients treated with immunotherapy. Acta Derm Venereol. 2019;99(2):206–10.PubMed

35.

Salemi R, Falzone L, Madonna G, Polesel J, Cina D, Mallardo D, et al. MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAF(V600E) mutation detected in circulating-free DNA. Front Pharmacol. 2018;9:856.PubMedPubMedCentral

36.

Herbreteau G, Vallee A, Knol AC, Theoleyre S, Quereux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265–76.PubMedPubMedCentral

37.

Shapochka D, Shapochka T, Seleznyov O, Matveeva A, Dudin V. Use of circulating tumor dna for detection of braf v600e mutation and treatment monitoring in melanoma patients. Georgian Med News. 2018;276:76–81.

38.

Ashida A, Sakaizawa K, Uhara H, Okuyama R. Circulating tumour DNA for monitoring treatment response to anti-PD-1 immunotherapy in melanoma patients. Acta Derm Venereol. 2017;97(10):1212–8.PubMed

39.

McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, et al. Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget. 2017;8(45):78890–900.PubMedPubMedCentral

40.

Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, et al. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. J Transl Med. 2019;17(1):303.PubMedPubMedCentral

41.

van Dessel LF, Vitale SR, Helmijr JCA, Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, et al. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Mol Oncol. 2019;13(2):392–402.PubMed

42.

Klump J, Phillipp U, Follo M, Eremin A, Lehmann H, Nestel S, et al. Extracellular vesicles or free circulating DNA: where to search for BRAF and cKIT mutations? Nanomedicine. 2018;14(3):875–82.PubMed

43.

• Garcia-Silva S, Benito-Martin A, Sanchez-Redondo S, Hernandez-Barranco A, Ximenez-Embun P, Nogues L, et al. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF (V600E) mutation. J Exp Med. 2019;216(5):1061–70 A clinical study where the investigators were able to detect BRAF^V600E mutation in the extracellular vesicles from lymphatic drainage of some melanoma patients who were at higher risk of cancer relapse.

44.

Broggi MAS, Maillat L, Clement CC, Bordry N, Corthesy P, Auger A, et al. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients. J Exp Med. 2019;216(5):1091–107.PubMedPubMedCentral

45.

Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, et al. S100-EPISPOT: a new tool to detect viable circulating melanoma cells. Cells. 2019;8(7):755.PubMedCentral

46.

Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. PLoS One. 2018;13(11):e0206942.PubMedPubMedCentral

47.

Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2019;26(7):1267–82.PubMed

48.

Mumford SL, Towler BP, Pashler AL, Gilleard O, Martin Y, Newbury SF. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules. 2018;8(2).

49.

Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262–78.PubMedPubMedCentral

50.

Pardini B, Sabo AA, Birolo G, Calin GA. Noncoding RNAs in extracellular fluids as cancer biomarkers: the new frontier of liquid biopsies. Cancers. 2019;11(8).

51.

Bennett DC. Genetics of melanoma progression: the rise and fall of cell senescence. Pigment Cell Melanoma Res. 2016;29(2):122–40.PubMed

52.

Huang JM, Chikeka I, Hornyak TJ. Melanocytic nevi and the genetic and epigenetic control of oncogene-induced senescence. Dermatol Clin. 2017;35(1):85–93.PubMedPubMedCentral

53.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, et al. Targeting the senescence-overriding cooperative activity of structurally unrelated H3K9 demethylases in melanoma. Cancer Cell. 2018;33(2):322–36.e8.PubMedPubMedCentral

54.

Sieben CJ, Sturmlechner I, van de Sluis B, van Deursen JM. Two-step senescence-focused cancer therapies. Trends Cell Biol. 2018;28(9):723–37.PubMedPubMedCentral

55.

Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNgamma pathways. Nat Rev Clin Oncol. 2019;16(9):549–62.PubMedPubMedCentral

56.

Joselow A, Lynn D, Terzian T, Box NF. Senescence-like phenotypes in human nevi. Methods Mol Biol. 2017;1534:175–84.PubMedPubMedCentral

57.

Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, et al. A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genet. 2017;13(8):e1006942.PubMedPubMedCentral

58.

Carvalho C, L'Hote V, Courbeyrette R, Kratassiouk G, Pinna G, Cintrat JC, et al. Glucocorticoids delay RAF-induced senescence promoted by EGR1. J Cell Sci. 2019;132(16).

59.

Kumar R, Njauw CN, Reddy BY, Ji Z, Rajadurai A, Klebanov N, et al. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene. 2019;38(18):3504–20.PubMedPubMedCentral

60.

Wang L, Leite de Oliveira R, Wang C, Fernandes Neto JM, Mainardi S, Evers B, et al. High-throughput functional genetic and compound screens identify targets for senescence induction in Cancer. Cell Rep. 2017;21(3):773–83.PubMed

61.

Lee WJ, Skalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, et al. Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discov. 2017;22(3):298–308.PubMed

62.

Sener E, Yildirim P, Tan A, Gokoz O, Tezel GG. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. Pathol Res Pract. 2017;213(5):522–30.PubMed

63.

Bruno W, Martinuzzi C, Andreotti V, Pastorino L, Spagnolo F, Dalmasso B, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry. Oncotarget. 2017;8(5):8069–82.PubMed

64.

O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron C. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol. 2017;70(11):935–40.PubMed

65.

Felisiak-Golabek A, Inaguma S, Kowalik A, Wasag B, Wang ZF, Zieba S, et al. SP174 antibody lacks specificity for NRAS Q61R and cross-reacts with HRAS and KRAS Q61R mutant proteins in malignant melanoma. Appl Immunohistochem Mol Morphol. 2018;26(1):40–5.PubMedPubMedCentral

66.

Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, et al. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform. Melanoma Res. 2018;28(2):96–104.PubMed

67.

Vallee A, Denis-Musquer M, Herbreteau G, Theoleyre S, Bossard C, Denis MG. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay. PLoS One. 2019;14(8):e0221123.PubMedPubMedCentral

68.

Chat-Uthai N, Vejvisithsakul P, Udommethaporn S, Meesiri P, Danthanawanit C, Wongchai Y, et al. Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PLoS One. 2018;13(6):e0198795.PubMedPubMedCentral

69.

•• Reiter JG, Makohon-Moore AP, Gerold JM, Heyde A, Attiyeh MA, Kohutek ZA, et al. Minimal functional driver gene heterogeneity among untreated metastases. Science (New York, NY). 2018;361(6406):1033–7 A clinical study on patients with different cancer types demonstarated that a large majority of driver gene mutations are common to all metastases and that portion which were not shared by all metastases are unlikely to have functional consequences.

70.

•• Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, et al. Patterns of genomic evolution in advanced melanoma. Nat Commun. 2018;9(1):2665 This clinical study showed only a small intermetastatic genetic heterogeneity in melanoma patients, with almost fully similar driver mutations between different lesions.

71.

•• Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, et al. Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. J Transl Med. 2019;17(1):289 This clinical study demonstrated a high concordance of mutational patterns when comparing the primary and metastatic cutaneous melanomas.

72.

Li X, Cai Y. Better prognostic determination and feature characterization of cutaneous melanoma through integrative genomic analysis. Aging. 2019;11(14):5081–107.PubMedPubMedCentral

73.

Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–36.PubMed

74.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80.PubMed

Titel: Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives
verfasst von: Nasr Alrabadi, MD, Msc, PhD
Razan Haddad, BPharm, Msc, PhDc
Ahmed K. Alomari, MD
Publikationsdatum: 01.03.2020
Verlag: Springer US
Erschienen in: Current Treatment Options in Oncology / Ausgabe 3/2020
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-020-0708-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives

Opinion statement

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Cellular Immunotherapy in Lymphoma: Beyond CART Cells

Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape

Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer

Evolving Definitions of Palliative Care: Upstream Migration or Confusion?

Opioids and Cancer Mortality

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie